352 related articles for article (PubMed ID: 33387577)
1. Species-specific differences in the inhibition of 11β-hydroxysteroid dehydrogenase 2 by itraconazole and posaconazole.
Inderbinen SG; Zogg M; Kley M; Smieško M; Odermatt A
Toxicol Appl Pharmacol; 2021 Feb; 412():115387. PubMed ID: 33387577
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of 11β-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole.
Beck KR; Bächler M; Vuorinen A; Wagner S; Akram M; Griesser U; Temml V; Klusonova P; Yamaguchi H; Schuster D; Odermatt A
Biochem Pharmacol; 2017 Apr; 130():93-103. PubMed ID: 28131847
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals.
Beck KR; Telisman L; van Koppen CJ; Thompson GR; Odermatt A
J Steroid Biochem Mol Biol; 2020 May; 199():105605. PubMed ID: 31982514
[TBL] [Abstract][Full Text] [Related]
4. In vitro methods to assess 11β-hydroxysteroid dehydrogenase type 2 activity.
Kley M; Moser SO; Winter DV; Odermatt A
Methods Enzymol; 2023; 689():167-200. PubMed ID: 37802570
[TBL] [Abstract][Full Text] [Related]
5. Species-specific differences in the inhibition of human and zebrafish 11β-hydroxysteroid dehydrogenase 2 by thiram and organotins.
Meyer A; Strajhar P; Murer C; Da Cunha T; Odermatt A
Toxicology; 2012 Nov; 301(1-3):72-8. PubMed ID: 22796344
[TBL] [Abstract][Full Text] [Related]
6. Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess.
Atanasov AG; Ignatova ID; Nashev LG; Dick B; Ferrari P; Frey FJ; Odermatt A
J Am Soc Nephrol; 2007 Apr; 18(4):1262-70. PubMed ID: 17314322
[TBL] [Abstract][Full Text] [Related]
7. Direct inhibition of bisphenols on human and rat 11β-hydroxysteroid dehydrogenase 2: Structure-activity relationship and docking analysis.
Zhang B; Wang S; Tang Y; Hu Z; Shi L; Lu J; Li H; Wang Y; Zhu Y; Lin H; Ge RS
Ecotoxicol Environ Saf; 2023 Apr; 254():114715. PubMed ID: 36871355
[TBL] [Abstract][Full Text] [Related]
8. Characterization of activity and binding mode of glycyrrhetinic acid derivatives inhibiting 11β-hydroxysteroid dehydrogenase type 2.
Kratschmar DV; Vuorinen A; Da Cunha T; Wolber G; Classen-Houben D; Doblhoff O; Schuster D; Odermatt A
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):129-42. PubMed ID: 21236343
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the study of 11β-Hydroxysteroid dehydrogenase type 2 (11β-HSD2)Inhibitors.
Zhou C; Ye F; Wu H; Ye H; Chen Q
Environ Toxicol Pharmacol; 2017 Jun; 52():47-53. PubMed ID: 28366868
[TBL] [Abstract][Full Text] [Related]
10. Organotins disrupt the 11beta-hydroxysteroid dehydrogenase type 2-dependent local inactivation of glucocorticoids.
Atanasov AG; Nashev LG; Tam S; Baker ME; Odermatt A
Environ Health Perspect; 2005 Nov; 113(11):1600-6. PubMed ID: 16263518
[TBL] [Abstract][Full Text] [Related]
11. 11β-HSD2 SUMOylation Modulates Cortisol-Induced Mineralocorticoid Receptor Nuclear Translocation Independently of Effects on Transactivation.
Jiménez-Canino R; Lorenzo-Díaz F; Odermatt A; Bailey MA; Livingstone DEW; Jaisser F; Farman N; Alvarez de la Rosa D
Endocrinology; 2017 Nov; 158(11):4047-4063. PubMed ID: 28938454
[TBL] [Abstract][Full Text] [Related]
12.
Thompson GR; Chang D; Wittenberg RR; McHardy I; Semrad A
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533238
[TBL] [Abstract][Full Text] [Related]
13. Apparent mineralocorticoid excess syndrome: an overview.
Palermo M; Quinkler M; Stewart PM
Arq Bras Endocrinol Metabol; 2004 Oct; 48(5):687-96. PubMed ID: 15761540
[TBL] [Abstract][Full Text] [Related]
14. Direct inhibition of human and rat 11β-hydroxysteroid dehydrogenase 2 by per- and polyfluoroalkyl substances: Structure-activity relationship and in silico docking analysis.
Zhao C; Wang S; Zhai Y; Wang M; Tang Y; Li H; Im YJ; Ge RS
Toxicology; 2023 Apr; 488():153484. PubMed ID: 36878351
[TBL] [Abstract][Full Text] [Related]
15. The anabolic androgenic steroid fluoxymesterone inhibits 11β-hydroxysteroid dehydrogenase 2-dependent glucocorticoid inactivation.
Fürstenberger C; Vuorinen A; Da Cunha T; Kratschmar DV; Saugy M; Schuster D; Odermatt A
Toxicol Sci; 2012 Apr; 126(2):353-61. PubMed ID: 22273746
[TBL] [Abstract][Full Text] [Related]
16. 11{beta}-Hydroxysteroid dehydrogenase 2 in rat leydig cells: its role in blunting glucocorticoid action at physiological levels of substrate.
Ge RS; Dong Q; Niu EM; Sottas CM; Hardy DO; Catterall JF; Latif SA; Morris DJ; Hardy MP
Endocrinology; 2005 Jun; 146(6):2657-64. PubMed ID: 15761036
[TBL] [Abstract][Full Text] [Related]
17. 11β-Hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension.
Campino C; Carvajal CA; Cornejo J; San Martín B; Olivieri O; Guidi G; Faccini G; Pasini F; Sateler J; Baudrand R; Mosso L; Owen GI; Kalergis AM; Padilla O; Fardella CE
Endocrine; 2010 Feb; 37(1):106-14. PubMed ID: 19882252
[TBL] [Abstract][Full Text] [Related]
18. Virtual screening as a strategy for the identification of xenobiotics disrupting corticosteroid action.
Nashev LG; Vuorinen A; Praxmarer L; Chantong B; Cereghetti D; Winiger R; Schuster D; Odermatt A
PLoS One; 2012; 7(10):e46958. PubMed ID: 23056542
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of novel 3-amino and 29-hydroxamic acid derivatives of glycyrrhetinic acid as selective 11β-hydroxysteroid dehydrogenase 2 inhibitors.
Stanetty C; Czollner L; Koller I; Shah P; Gaware R; Cunha TD; Odermatt A; Jordis U; Kosma P; Classen-Houben D
Bioorg Med Chem; 2010 Nov; 18(21):7522-41. PubMed ID: 20851614
[TBL] [Abstract][Full Text] [Related]
20. Structure-dependent inhibition of human and rat 11beta-hydroxysteroid dehydrogenase 2 activities by phthalates.
Zhao B; Chu Y; Huang Y; Hardy DO; Lin S; Ge RS
Chem Biol Interact; 2010 Jan; 183(1):79-84. PubMed ID: 19786001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
